Skip to main content
MedPacto, Inc. logo

MedPacto, Inc. — Investor Relations & Filings

Ticker · 235980 ISIN · KR7235980000 KO Manufacturing
Open in API
Filings indexed 261 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 235980

About MedPacto, Inc.

http://www.medpacto.com/eng/

MedPacto, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of first-in-class therapies. The company leverages a biomarker-driven and genome-based platform to create personalized treatments, aiming to advance precision medicine. Its primary therapeutic areas include oncology and autoimmune diseases, with pipeline expansion into metabolic and bone joint disorders. MedPacto's research focuses on novel mechanisms, such as modulating the tumor microenvironment, to address incurable diseases and overcome the limitations of existing treatments.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled a "분기보고서 (제14기)" covering the period January 1 to March 31, 2026, filed with the Financial Services Commission and Korea Exchange. It includes detailed company overview, business description, quarterly financial tables, sales, risk management, and contracts. It is a substantive quarterly financial report rather than an announcement. Therefore, it matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 65% confidence The document is an amended regulatory filing (“정정신고”) reporting corrections to a previously submitted share-based compensation grant (“주식매수선택권 부여”) to the Financial Supervisory Service/KRX. It details adjustments to the number of stock options granted, exercise price, fair value, and participants, which constitutes a future issuance of shares (capital change). This matches the category for announcements regarding new share issues or other capital changes (SHA).
2026-03-26 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a Korean regulatory disclosure titled “주식매수선택권 부여에 관한 신고” (Stock Option Grant Report) and specifically an amendment (“정정신고”) to a prior filing. It details changes to the number of options granted, exercise price adjustments, and recipient information. It is not an annual or interim financial report, earnings release, management discussion, or AGM material; nor is it a personal insider trade report (DIRS) since it covers company-wide option grants. Rather, it announces the issuance (grant) of new stock options and corresponding potential share issuance under the company’s capital structure. This aligns with “Share Issue/Capital Change” (SHA).
2026-03-26 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a statutory filing (“신고”) to the Financial Services Commission/Korea Exchange detailing the grant of stock options (주식매수선택권 부여) and corrections to a previously filed notice. This is not an earnings release, management report, or AGM material, but rather a formal notification of new equity issuance via stock options. Under the classification scheme, notices of new share issues or capital changes (including option grants) map to Share Issue/Capital Change (SHA).
2026-03-26 Korean
[기재정정]주식매수선택권부여에관한신고
Transaction in Own Shares Classification · 80% confidence The document is a Korean regulatory filing titled “주식매수선택권 부여에 관한 신고” (stock option grant report), including a correction of previously filed option allocations. It is not an earnings release, proxy, or AGM material, but a disclosure of a transaction in the company’s own shares (employee stock‐option issuance). Under the given taxonomy, this falls under 29. Transaction in Own Shares (POS).
2026-03-26 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 65% confidence The document is a regulatory disclosure filed with the Financial Services Commission/Korea Exchange regarding the amendment (“정정 신고”) to a previously submitted notice of stock‐option grants (“주식매수선택권 부여에 관한 신고”). It details corrected recipient counts and share quantities under the option plan. This is not an earnings release, annual report, board change, or insider trade report but is directly related to an equity‐linked instrument issuance (stock options), fitting the Share Issue/Capital Change category.
2026-03-26 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.